New drug JY016 targets EGFR-Positive cancers in early trial
NCT ID NCT07510841
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called JY016 in people with advanced solid tumors that have a protein called EGFR. The goal is to find a safe dose and see if the drug can shrink tumors. The trial includes people with several cancer types, such as pancreatic, lung, and colorectal cancer, who have not responded to standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.